Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy
Cognito Therapeutics has partnered with Ochsner Health to explore the integration of innovative Alzheimer’s therapies into clinical practice through a new initiative called the “Brain Health Collaboratory.” This collaboration aims to assess Cognito’s investigational Spectris device, which employs synchronized light and sound stimulation to target brain activity linked to cognitive decline. The initiative will leverage Ochsner’s extensive healthcare network, encompassing 47 hospitals and numerous care sites, to generate evidence on clinical outcomes and scalability of these emerging treatments.
This partnership is significant for the longevity and healthspan field as it represents a step towards translating neurotechnology research into practical applications. By embedding the Spectris device within a diverse patient population, the initiative seeks to provide insights into how non-invasive neuromodulation therapies can be effectively implemented in real-world settings, potentially improving patient outcomes and expanding access to innovative treatments.
A key takeaway from this collaboration is the development of a “Brain Health Index,” which will track cognitive performance and treatment responses, highlighting the importance of real-world evidence in the adoption of new therapies for Alzheimer’s disease and other neurological conditions.